Latest Immunosuppressants Stories
- New data at AAD shows 7 out of 10 psoriasis patients who were PASI 75 responders at 52 weeks achieved clear to almost clear skin (PASI 90) after two years of Cosentyx 300 mg treatment
- Nearly double the percentage of patients on BI 655066 with clear or almost clear skin (PASI 90) after 12 weeks vs.
- Phase IIIb CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx(TM) (secukinumab) compared to Stelara® (ustekinumab) at Week 16
DALLAS, March 19, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "PharmaPoint: Rheumatoid Arthritis - US and 5EU Drug Forecast and Market Analysis to 2023" report provides
DALLAS, March 18, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023" market research report provides
Pivotal Results Comparing Brodalumab With Stelara® (Ustekinumab) and Placebo to be Presented in Late-Breaking Session THOUSAND OAKS, Calif., March 17, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN)
- 22 abstracts further evaluate the safety, efficacy of HUMIRA in psoriatic arthritis and moderate to severe chronic plaque psoriasis and investigational use of HUMIRA for the treatment of moderate
Study in New England Journal of Medicine Examines Outcomes of Over 18,000 Patients with Coronary Artery Disease NEW YORK, March 16, 2015 /PRNewswire-USNewswire/ -- Newer drug-coated
If authorized, SB2 will be marketed in Europe by Biogen Idec INCHEON, South Korea, March 13, 2015 /PRNewswire/ -- Samsung Bioepis Co., Ltd., today announced that the Marketing Authorization
OTTAWA, March 11, 2015 /CNW/ - The issue: Mylan Pharmaceuticals ULC, in consultation with Health Canada, is voluntarily recalling one lot of Methotrexate Injection USP 50 mg/2
- A hairdresser.